Target audience: Gd-based T1 agent development for high fields, basic science studies, chemistry.
1
Methods: We investigated applications of the alanine analogue of Gd(DOTA), Gd(DOTAla). Fmoc protected DOTAla suitable for solid phase peptide synthesis was synthesized and integrated into polypeptide structures containing 1-3 Gd(DOTAla) complexes (GdL1, Gd 2 L2, Gd 3 L3). Water exchange kinetics for the inner-sphere water ligand were determined by measurement of the temperature dependence of the transverse relaxation time T 2 of H 2 17 O in the presence and absence of GdL1. Relaxivities were determined through measurement of T 1 using inversion recovery at different field strengths ranging from 0.47 T to 11.7T. To address kinetic inertness, we measured the full transchelation of Gd(III) from the complexes GdL1, Gd 2 L2 Gd 3 L3 to a DTPA derivative with higher thermodynamic stability at pH 3 and 37 °C.
Results:
The mean water residency time at 37 °C was found to be optimal (τ M = 17 ± 2 ns) for relaxivity. The facile integration of the DOTAla into polypeptide structures allowed investigation of a variety of multimeric structures. Relaxivity was determined for 6 new compounds along with FDA-approved agents gadofosveset and gadoteridol at 5 magnetic fields (0.47 -11.7T). The trimers performed best at all fields: r 1 = 12.9 mM -1 s -1 per Gd for Gd 3 L3 at 1.4T, 37 °C. T 1 measurements indicated that Gd 3 L3 shows greater relaxivity at low, intermediate and high fields than the clinically used small molecule contrast agent gadoteridol while also outperforming gadofosveset/HSA at intermediate and high fields (Figure 1 ).
Discussion and Conclusion:
Gd 3 L3 is superior to commercial contrast agents gadoteridol and gadofosveset /HSA (human serum albumin) at high fields. The modularity of design, the ease of solid phase synthesis, high kinetic inertness (t 1/2 = 61±4h) for Gd 3 L3), and optimal water exchange rate renders the Gd(DOTAla) scaffold a suitable platform for the development of high field T 1 agents based on Gd. 
